Hypoxia-activated prodrugs in cancer therapy: progress to the clinic
Published 2010 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Hypoxia-activated prodrugs in cancer therapy: progress to the clinic
Authors
Keywords
-
Journal
Future Oncology
Volume 6, Issue 3, Pages 419-428
Publisher
Future Medicine Ltd
Online
2010-03-11
DOI
10.2217/fon.10.1
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Hypoxic regulation of mRNA expression
- (2011) Lawrence Gardner et al. CELL CYCLE
- Prediction of Tumour Tissue Diffusion Coefficients of Hypoxia-Activated Prodrugs from Physicochemical Parameters
- (2009) Frederik B. Pruijn et al. AUSTRALIAN JOURNAL OF CHEMISTRY
- A phase I trial of PR-104, a nitrogen mustard prodrug activated by both hypoxia and aldo-keto reductase 1C3, in patients with solid tumors
- (2009) Michael B. Jameson et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- The Hypoxia-Activated ProDrug AQ4N Penetrates Deeply in Tumor Tissues and Complements the Limited Distribution of Mitoxantrone
- (2009) O. Tredan et al. CANCER RESEARCH
- DNA Cross-Links in Human Tumor Cells Exposed to the Prodrug PR-104A: Relationships to Hypoxia, Bioreductive Metabolism, and Cytotoxicity
- (2009) R. S. Singleton et al. CANCER RESEARCH
- Phase II Study of Tirapazamine, Cisplatin, and Etoposide and Concurrent Thoracic Radiotherapy for Limited-Stage Small-Cell Lung Cancer: SWOG 0222
- (2009) Quynh-Thu X. Le et al. JOURNAL OF CLINICAL ONCOLOGY
- Spin Trapping of Radicals Other Than the•OH Radical upon Reduction of the Anticancer Agent Tirapazamine by Cytochrome P450Reductase
- (2009) Sujata S. Shinde et al. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
- Effects of cytokine-induced macrophages on the response of tumor cells to banoxantrone (AQ4N)
- (2009) M. Mehibel et al. MOLECULAR CANCER THERAPEUTICS
- Roles of DNA repair and reductase activity in the cytotoxicity of the hypoxia-activated dinitrobenzamide mustard PR-104A
- (2009) Y. Gu et al. MOLECULAR CANCER THERAPEUTICS
- Factors underlying sensitivity of cancers to small-molecule kinase inhibitors
- (2009) Pasi A. Jänne et al. NATURE REVIEWS DRUG DISCOVERY
- Response of Multiple Recurrent TaT1 Bladder Cancer to Intravesical Apaziquone (EO9): Comparative Analysis of Tumor Recurrence Rates
- (2009) Arun Jain et al. UROLOGY
- Two-year follow-up of the phase II marker lesion study of intravesical apaziquone for patients with non-muscle invasive bladder cancer
- (2009) Kees Hendricksen et al. WORLD JOURNAL OF UROLOGY
- Homologous Recombination Is the Principal Pathway for the Repair of DNA Damage Induced by Tirapazamine in Mammalian Cells
- (2008) J. W. Evans et al. CANCER RESEARCH
- Hypoxia-Selective Targeting by the Bioreductive Prodrug AQ4N in Patients with Solid Tumors: Results of a Phase I Study
- (2008) M. R. Albertella et al. CLINICAL CANCER RESEARCH
- A Phase 1 Open-Label, Accelerated Dose-Escalation Study of the Hypoxia-Activated Prodrug AQ4N in Patients with Advanced Malignancies
- (2008) K. P. Papadopoulos et al. CLINICAL CANCER RESEARCH
- Tirapazamine: a novel agent targeting hypoxic tumor cells
- (2008) Srini B Reddy et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Reductive Heme-Dependent Activation of theN-Oxide Prodrug AQ4N by Nitric Oxide Synthase
- (2008) Clinton R. Nishida et al. JOURNAL OF MEDICINAL CHEMISTRY
- Tricyclic [1,2,4]Triazine 1,4-Dioxides As Hypoxia Selective Cytotoxins
- (2008) Michael P. Hay et al. JOURNAL OF MEDICINAL CHEMISTRY
- Potent and Highly Selective Hypoxia-Activated Achiral Phosphoramidate Mustards as Anticancer Drugs
- (2008) Jian-Xin Duan et al. JOURNAL OF MEDICINAL CHEMISTRY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now